| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/511035 |
| P8608 | Fatcat ID | release_5mlipimed5g7xgpykgyswwlaca |
| P698 | PubMed publication ID | 17243065 |
| P5875 | ResearchGate publication ID | 6560177 |
| P50 | author | Benigno Rodriguez | Q42870636 |
| Daniel Kuritzkes | Q88453812 | ||
| P2093 | author name string | Michael Hughes | |
| Roy M Gulick | |||
| Joseph Timpone | |||
| Robert Gross | |||
| Zhaohui Su | |||
| Charles Flexner | |||
| Paul R Skolnik | |||
| Eoin Coakley | |||
| Timothy J Wilkin | |||
| Catherine Godfrey | |||
| Wayne Greaves | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV/AIDS | Q12199 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 591-595 | |
| P577 | publication date | 2007-01-17 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. | |
| P478 | volume | 44 |
| Q37410812 | A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains |
| Q28542548 | A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART |
| Q37246041 | AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics |
| Q28300187 | Access denied? The status of co-receptor inhibition to counter HIV entry |
| Q34786687 | Analysis of HIV tropism in Ugandan infants |
| Q33798442 | Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody |
| Q36020992 | Antiretroviral drugs: critical issues and recent advances |
| Q42061595 | Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions |
| Q27693321 | Bioinformatic analysis of HIV-1 entry and pathogenesis |
| Q80162610 | Bioinformatics prediction of HIV coreceptor usage |
| Q44189768 | CCR5 antagonists: a new class of antiretrovirals |
| Q35199475 | CCR5 inhibitors: Emerging promising HIV therapeutic strategy |
| Q37252113 | Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults |
| Q34437126 | Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. |
| Q35441620 | Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains |
| Q27691426 | Clinical significance of HIV-1 coreceptor usage |
| Q37409937 | Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays |
| Q38610610 | Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein |
| Q42256490 | Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates |
| Q35947561 | Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. |
| Q37605946 | Coreceptor usage of Chinese HIV-1 and impact of X4/DM transmission clusters among recently infected men who have sex with men. |
| Q39511996 | Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future |
| Q39177719 | Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry |
| Q51736944 | Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. |
| Q34262112 | Differential responses of plasmacytoid dendritic cells to influenza virus and distinct viral pathogens |
| Q60952499 | Disparate impact on CD4 T cell count by two distinct HIV-1 phylogenetic clusters from the same clade |
| Q42757842 | Drug resistant HIV. |
| Q37365672 | Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study |
| Q33886716 | Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases |
| Q33973857 | Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection |
| Q41995185 | Evolution of CCR5 use before and during coreceptor switching |
| Q42206476 | Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure |
| Q37288573 | Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients |
| Q60951107 | Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection |
| Q36181852 | Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. |
| Q35071940 | Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study |
| Q39338065 | Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1. |
| Q34654433 | HIV entry inhibitors. |
| Q34280466 | HIV-1 antiretroviral resistance: scientific principles and clinical applications |
| Q30245693 | HIV-1 drug resistance and resistance testing |
| Q36900010 | HIV-1 drug resistance mutations: an updated framework for the second decade of HAART |
| Q24645525 | HIV-1 entry inhibitors: an overview |
| Q33513977 | HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. |
| Q33521125 | HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples |
| Q34505231 | HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients |
| Q37525642 | HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations |
| Q40548483 | High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia |
| Q36484034 | Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques |
| Q35364051 | Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B |
| Q34846620 | Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. |
| Q42140292 | Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors |
| Q34806062 | Maraviroc for previously treated patients with R5 HIV-1 infection |
| Q37634319 | Maraviroc in the treatment of HIV infection. |
| Q34606050 | Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection |
| Q37961181 | Mechanism of HIV antiretroviral drugs progress toward drug resistance |
| Q37581155 | Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. |
| Q36191170 | Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1. |
| Q36823525 | New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists |
| Q37578904 | New developments in HIV drug resistance |
| Q37385347 | Novel targets for antiretroviral therapy: clinical progress to date |
| Q37662415 | Peripheral neuropathy in ART-experienced patients: prevalence and risk factors |
| Q35557216 | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| Q34150882 | Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults |
| Q37182431 | Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy |
| Q37705023 | Platelet-derived chemokines: pathophysiology and therapeutic aspects |
| Q42926976 | Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies |
| Q39556338 | Preclinical discovery and development of maraviroc for the treatment of HIV. |
| Q35964202 | Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana |
| Q39267946 | Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain |
| Q38808224 | Quantifying CD4/CCR5 Usage Efficiency of HIV-1 Env Using the Affinofile System |
| Q36747765 | R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch |
| Q38053111 | Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals. |
| Q35274968 | Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. |
| Q43998763 | Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial |
| Q35052934 | Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage |
| Q37827167 | Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010. |
| Q37034602 | Targeting HIV attachment and entry for therapy |
| Q28259321 | The design of drugs for HIV and HCV |
| Q35818419 | The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa |
| Q39580883 | The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen |
| Q34051325 | Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients |
| Q44470116 | Trofile HIV co-receptor usage assay. |
| Q33869686 | Tropism testing in the clinical management of HIV-1 infection |
| Q43187699 | Use of a commercial HIV co-receptor tropism assay in clinical practice |
| Q38969711 | Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism |
| Q31117473 | X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process |
| Q39096179 | X4-tropic human immunodeficiency virus IIIB utilizes CXCR4 as coreceptor, as distinct from R5X4-tropic viruses |
Search more.